Compounds, Compositions, and Methods for Preventing Metastasis of Cancer Cells
A patent family: one line of work, grouped by real continuity rather than by a technology label
inferred from titles. 4 of these applications claim priority to application PCT/US2010/020822, filed Jan 12, 2010. A shared origin can cover several different claimed inventions, which is why members here may not share a title. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
| Patent | Title | Holder | Status | Expires | Time remaining | Confidence |
|---|---|---|---|---|---|---|
| US 8,569,348 | Compounds, Compositions, and Methods for Preventing Metastasis of Cancer Cells In force · High confidence | Eyepoint, Inc. | In force | High confidence | ||
| US 8,883,832 | Compounds, Compositions, and Methods for Preventing Metastasis of Cancer Cells In force · High confidence | Eyepoint, Inc. | In force | High confidence | ||
| US 9,174,950 | Compounds, Compositions, and Methods for Preventing Metastasis of Cancer Cells In force · High confidence | Eyepoint, Inc. | In force | High confidence | ||
| US 9,949,956 | Compounds, Compositions, and Methods for Preventing Metasasis of Cancer Cells In force · High confidence | Eyepoint, Inc. | In force | High confidence |
4 of 4 records shown. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
Updated Nov 15, 2026 · includes USPTO assignment & status data published Nov 15, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.